AOD 9604 ZPHC — 12.5 mg (5 vials × 2.5 mg)

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region (amino acids 176–191) of human growth hormone (hGH). It was developed to replicate the fat-reducing (lipolytic) effects of growth hormone without triggering its growth-promoting or insulin-altering actions.

AOD-9604 works primarily by stimulating lipolysis (the breakdown of stored fat) and inhibiting lipogenesis (the formation and storage of new fat). It activates pathways involved in fat metabolism while avoiding interaction with growth hormone receptors responsible for muscle growth, bone growth, or significant hormonal changes. Because of this selective action, it does not significantly affect blood glucose levels, insulin sensitivity, or IGF-1 production.

Originally researched as a potential anti-obesity treatment, AOD-9604 showed promising results in preclinical and early human studies, demonstrating reduced body fat and improved fat metabolism with a strong safety profile. It has been investigated for both injectable and oral (sublingual or capsule) forms, with good stability compared to full hGH.

AOD-9604 is not approved as a prescription medication for weight loss in most countries, but it is widely used in research settings and by individuals seeking fat loss support. It is non-anabolic, non-androgenic, and does not promote muscle gain directly. Reported side effects are generally mild and uncommon, especially when compared to full growth hormone therapy.

In summary, AOD-9604 is a targeted fat-loss peptide designed to enhance fat metabolism safely, without the systemic hormonal effects associated with human growth hormone.